Enanta Pharmaceuticals to Participate in Two Investor Conferences in September

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ: ENTA), a biotechnology company specializing in small molecule drugs for viral infections and liver diseases, will feature CEO Jay R. Luly, Ph.D., at two investor conferences in September 2022. He will present at the Wells Fargo Healthcare Conference on September 8 at 3:10 p.m. ET, followed by a fireside chat at the Baird Global Healthcare Conference on September 13 at 9:40 a.m. ET. Live webcasts will be available on Enanta’s website, with replays accessible for 30 days after the events.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in September:

• Wells Fargo Healthcare Conference: Presentation at 3:10 p.m. ET on September 8, 2022
• Baird Global Healthcare Conference: Fireside Chat at 9:40 a.m. ET on September 13, 2022

A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. Replays of the webcasts will be available following the presentations and will be archived for approximately 30 days.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005100/en/

Media and Investor Contact

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When will Enanta Pharmaceuticals present at the Wells Fargo Healthcare Conference?

Enanta Pharmaceuticals will present at the Wells Fargo Healthcare Conference on September 8, 2022, at 3:10 p.m. ET.

What time is Enanta's fireside chat at the Baird Global Healthcare Conference?

The fireside chat at the Baird Global Healthcare Conference will take place on September 13, 2022, at 9:40 a.m. ET.

Where can I watch the Enanta Pharmaceuticals investor conference webcasts?

The webcasts for Enanta Pharmaceuticals' investor conferences can be accessed from the 'Events and Presentations' section on their website.

How long will the recorded webcasts of Enanta's presentations be available?

The recorded webcasts of Enanta's presentations will be available for approximately 30 days after the events.

What are the main disease targets of Enanta Pharmaceuticals' research?

Enanta Pharmaceuticals is focusing on viral infections, including respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and hepatitis B virus (HBV).